Evidence map›Paper›PMID 41881311›Full record

ArticleMolecular metabolism2026

Dynamic evaluation of the glycolytic determinants LDH-A and GLUT-1 enhances prognostic significance and their inhibition affects the growth of mesothelioma spheroids.

Marika A Franczak, Federica Borea, Valentina Donati, Marta Aliprandi, Amir Avan, Valentina Doldi, Giulia Bononi, Kin Yip Tam, Carlotta Granchi, Ryszard T Smolenski and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Marika A FranczakDepartment of Biochemistry, Medical University of Gdansk, Poland; Department of Medical Oncology, Amsterdam University Medical Centers, location VUmc, Cancer Center Amsterdam, the Netherlands.
Federica BoreaIRCCS Humanitas Research Hospital, Humanitas Cancer Center, Rozzano, Milan, Italy.
Valentina DonatiUnit of Pathological Anatomy 2, Azienda Ospedaliero-Universitaria Pisana, 56100 Pisa, Italy.
Marta AliprandiIRCCS Humanitas Research Hospital, Humanitas Cancer Center, Rozzano, Milan, Italy.
Amir AvanMetabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Valentina DoldiMolecular Pharmacology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
Giulia BononiDipartimento di Farmacia, Università di Pisa, Pisa, Italy.
Kin Yip TamFaculty of Health Sciences, University of Macau, Taipa, Macau.
Carlotta GranchiDipartimento di Farmacia, Università di Pisa, Pisa, Italy.
Ryszard T SmolenskiDepartment of Biochemistry, Medical University of Gdansk, Poland.
Paolo A ZucaliIRCCS Humanitas Research Hospital, Humanitas Cancer Center, Rozzano, Milan, Italy.
Filippo MinutoloDipartimento di Farmacia, Università di Pisa, Pisa, Italy.
Godefridus J PetersDepartment of Biochemistry, Medical University of Gdansk, Poland; Department of Medical Oncology, Amsterdam University Medical Centers, location VUmc, Cancer Center Amsterdam, the Netherlands. Electronic address: godefridus.peters@gumed.edu.pl.
Elisa GiovannettiDepartment of Medical Oncology, Amsterdam University Medical Centers, location VUmc, Cancer Center Amsterdam, the Netherlands; Fondazione Pisana per la Scienza, Pisa, Italy. Electronic address: e.giovannetti@amsterdamumc.nl.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Energy metabolism plays a crucial role in determining the aggressiveness of cancer. In this study, we assessed the impact of drug-induced modulation on the expression and prognostic significance of crucial factors involved in glycolytic metabolism: lactate dehydrogenase A (LDH-A) and glucose transporter type 1 (GLUT-1). In patient samples diagnosed with pleural Malignant Mesothelioma (MM), expression levels of LDH-A and GLUT-1 were studied both at baseline and after platinum-based-chemotherapy. High GLUT-1 and LDH-A levels were associated with shorter survival, and chemotherapy increased GLUT-1 expression, further correlating with poor prognosis. Utilizing LDH-A (NHI-2) and GLUT-1 (PGL14) inhibitors, we examined their effects on migration and apoptosis in immortalized (H2052, H2452) and primary (STO, MESO-II) MM cells. PGL14 and NHI-2 decreased migration, increased reactive oxygen species (ROS) and apoptosis rates. Inhibitors, both single and in combination, disintegrated the MM spheroids, while the bioluminescence from spheroid-forming cells decreased from 1.3 × 10

Indexed as

Glucose Transporter Type 1Lactate Dehydrogenase 5L-Lactate DehydrogenaseLung NeoplasmsMesotheliomaMesothelioma, MalignantApoptosisCell Line, TumorCell MovementCell ProliferationGlycolysisHumansIsoenzymesPleural NeoplasmsPrognosisReactive Oxygen SpeciesGlucose Transporter Type 1IsoenzymesLactate Dehydrogenase 5LDHA protein, humanL-Lactate DehydrogenaseReactive Oxygen SpeciesSLC2A1 protein, humanChemoresistanceGlucose transporter-1Lactate dehydrogenase-AMalignant mesotheliomaNew inhibitors of glycolytic metabolism

Identifiers

PMID41881311
PMCPMC13084315

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.